Endocrinology Research Analysis
Q3 2025 endocrinology was defined by less-frequent, high-efficacy incretin-based therapeutics, mechanistic immunometabolism, and enabling measurement tools. Monthly incretin-pathway dosing achieved durable double-digit weight loss, while once-weekly basal insulin simplified initiation with fewer hypoglycemic events. Mechanistic advances mapped islet microcircuitry and introduced dual GLP1R/GIPR fluorescent probes, accelerating target engagement science. Cross-organ immunometabolic nodes (ACLY in
Summary
Q3 2025 endocrinology was defined by less-frequent, high-efficacy incretin-based therapeutics, mechanistic immunometabolism, and enabling measurement tools. Monthly incretin-pathway dosing achieved durable double-digit weight loss, while once-weekly basal insulin simplified initiation with fewer hypoglycemic events. Mechanistic advances mapped islet microcircuitry and introduced dual GLP1R/GIPR fluorescent probes, accelerating target engagement science. Cross-organ immunometabolic nodes (ACLY in MASH-HCC; PGK1 in diabetic kidney disease) crystallized as tractable targets, and energy-expenditure pharmacology progressed via a creatine-cycle thermogenic agent (SANA). Multi-modal AI deep phenotyping showed strong promise for risk stratification and biomarker discovery, pointing toward molecularly guided, lower-burden care.
Selected Articles
1. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
A 52-week randomized, double-blind phase 2 trial showed once-monthly maridebart cafraglutide achieved 12–16% mean weight loss (and HbA1c reductions in T2D), with manageable GI events mitigated by dose escalation.
Impact: Provides rigorous evidence that monthly incretin-pathway dosing can deliver durable, clinically meaningful weight loss, reframing dosing frequency expectations.
Clinical Implications: Expands options for patients seeking large weight loss with lower injection burden; supports proactive GI management and comparative evaluation against weekly regimens.
Key Findings
- 12.3–16.2% weight loss in obesity and 8.4–12.3% with T2D at 52 weeks
- Meaningful HbA1c reductions in T2D subgroup
- GI AEs common but manageable; dose escalation improved tolerability
2. ACLY inhibition promotes tumour immunity and suppresses liver cancer.
In MASH-driven HCC models, ACLY inhibition reprogrammed the immunosuppressive microenvironment, enhanced anti-tumor immunity, and suppressed tumor growth, nominating ACLY as an actionable immunometabolic node.
Impact: Positions immunometabolism at the metabolic–oncology interface with a tractable target and translational strategy to convert non-inflamed tumors into immunoresponsive states.
Clinical Implications: Supports clinical testing of ACLY inhibitors to enhance immunotherapy efficacy in MASH-HCC and potentially other metabolically conditioned tumors.
Key Findings
- ACLY inhibition enhanced anti-tumor immunity in MASH-HCC models
- Suppressed liver cancer growth in preclinical systems
- Establishes ACLY as an immunometabolic therapeutic node
3. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
A 68-week, multicountry phase 3 trial showed once-weekly cagrilintide–semaglutide achieved −13.7% mean weight change and high rates of HbA1c ≤6.5%, with mostly mild–moderate, transient GI adverse events.
Impact: Delivers definitive evidence that dual-agonist incretin strategies yield large, clinically meaningful weight loss alongside tight glycemic control in T2D with obesity.
Clinical Implications: Supports adoption of dual-agonist regimens for concurrent weight and glycemic targets, with anticipatory GI management and patient counseling.
Key Findings
- Mean weight change −13.7% vs −3.4% with placebo at 68 weeks
- HbA1c ≤6.5% achieved in 73.5% vs 15.9% with placebo
- GI adverse events were frequent but mostly mild–moderate and transient
4. Deep phenotyping of health-disease continuum in the Human Phenotype Project.
A large prospective deep-phenotyping cohort integrated lifestyle, CGM, imaging, and multi-omics, presenting a self-supervised multi-modal AI model that outperformed existing methods for disease onset prediction.
Impact: Establishes a scalable resource and AI framework to materially improve metabolic risk prediction and biomarker discovery, enabling personalized metabolic medicine.
Clinical Implications: Facilitates earlier identification of high-risk metabolic phenotypes and integration of CGM-linked AI decision support into clinical workflows.
Key Findings
- Baseline deep phenotyping completed in >13,000 of ~28,000 enrollees
- Age- and ethnicity-associated molecular phenotypes and disease signatures identified
- Self-supervised AI trained on diet and CGM outperformed existing predictors
5. Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners.
Integrated translational work identifies PGK1 as a central driver of DKD via enzymatic 3‑PG–GPX1–NLRP3 activation and a non‑enzymatic Aldh1l1–UNC5CL inflammatory axis, with repurposable antagonists preventing DKD in models.
Impact: Nominates a druggable metabolic–inflammatory hub with immediate translational leads, reframing DKD pathogenesis and therapy.
Clinical Implications: Supports early-phase testing of PGK1 antagonists with 3‑PG and inflammasome biomarkers to complement current reno-metabolic therapies.
Key Findings
- Tubule-specific PGK1 manipulation modulated DKD severity in vivo
- Dual enzymatic and non-enzymatic inflammatory mechanisms identified
- Repurposable PGK1 antagonists prevented DKD in animal models
6. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
In a 52-week phase 3 trial, once-weekly fixed-dose efsitora was noninferior to daily glargine for HbA1c reduction, with fewer hypoglycemic events and simpler titration.
Impact: Validates a simplified, lower-burden basal insulin initiation paradigm with safety advantages.
Clinical Implications: Offers a practical weekly option for insulin-naïve adults, potentially improving adherence and safety.
Key Findings
- Noninferior HbA1c reduction vs daily glargine at 52 weeks
- Lower rate of clinically significant/severe hypoglycemia
- Fewer dose adjustments and lower weekly insulin burden
7. Gene regulatory activity associated with polycystic ovary syndrome revealed DENND1A-dependent testosterone production.
Massively parallel reporter assays and CRISPR epigenome editing fine-mapped PCOS regulatory elements, showing that upregulation of endogenous DENND1A elevates testosterone in adrenal models, linking noncoding variation to hyperandrogenism.
Impact: Provides a functional causal bridge from GWAS regulatory variants to a core endocrine phenotype, enabling mechanism-based target discovery in PCOS.
Clinical Implications: Supports genetic risk stratification and development of DENND1A-centered interventions to reduce hyperandrogenism.
Key Findings
- Functional regulatory elements mapped at DENND1A and other PCOS loci
- CRISPR upregulation of endogenous DENND1A elevated testosterone
- Links noncoding regulatory variation to hyperandrogenism
8. A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.
SANA activated creatine-dependent thermogenesis, improved mitochondrial respiration, and reduced steatosis/insulin resistance in models; phase 1A/B randomized data showed favorable safety with early weight and glucose signals.
Impact: Introduces a first-in-class energy-expenditure mechanism (creatine cycle) that could complement incretin therapy.
Clinical Implications: If validated, SANA may be combined with incretins to augment weight loss and metabolic health; long-term cardiometabolic safety must be established.
Key Findings
- Activates creatine-dependent thermogenesis with improved mitochondrial respiration
- Reduces hepatic steatosis and insulin resistance in DIO models
- Phase 1A/B randomized data support safety and early efficacy signals
9. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.
Lipidated and non-lipidated fluorescent dual GLP1R/GIPR agonist probes retained potent dual agonism and enabled in vivo labeling of islet cells and GLP1R-rich brain regions, allowing direct mapping of incretin engagement.
Impact: Delivers first-in-class molecular tools to visualize dual-agonist target engagement, directly informing dose optimization, safety profiling, and next-generation design.
Clinical Implications: Enables preclinical target validation and off-target safety assessments for dual incretin agonists, guiding translational dosing and tissue exposure studies.
Key Findings
- Developed potent dual-agonist fluorescent probes (daLUXendins)
- In vivo labeling of rodent and human islet cells and GLP1R-rich brain regions
- Reduces receptor-selectivity bias and maps target engagement directly
10. Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication.
Mechanistic work revealed GLP1R enrichment in nanodomains at alpha–beta contacts; adjacent beta cells pre-internalize GLP1R at low glucose to sense micromolar glucagon, amplifying paracrine signaling.
Impact: Uncovers receptor-trafficking logic that organizes islet paracrine communication, informing design and dosing of incretin-based and co-agonist therapies.
Clinical Implications: Supports spatially informed dosing strategies and co-agonist designs that better leverage alpha–beta microcircuitry.
Key Findings
- GLP1R forms nanodomains at beta-cell membranes contacting alpha cells
- Pre-internalized GLP1R enables sensing of micromolar glucagon at low glucose
- Spatial receptor dynamics amplify alpha-to-beta paracrine signaling